STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXCM
  4. [Form 4] DEXCOM INC Insider Trading Activity

Dexcom (NASDAQ: DXCM) chair sells 26,756 shares around $90

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

DEXCOM INC (DXCM) Executive Chair Kevin R. Sayer reported open-market sales of a total of 26,756 shares of common stock on August 20, 2026, in three transactions at weighted average prices of about $89.71, $90.78, and $91.41. These sales were made under a Rule 10b5-1 trading plan adopted on February 18, 2026. Sayer continues to hold equity awards, including 106,972 unvested restricted stock units with grants from 2024–2026 that vest through dates in 2027 and 2028.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider SAYER KEVIN R
Role Executive Chair
Sold 26,756 shs ($2.41M)
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 19,308 $89.706 $1.73M
Sale Common Stock F1, F4, F3 7,351 $90.7811 $667K
Sale Common Stock F1, F3 97 $91.41 $9K
Holdings After Transaction: Common Stock — 302,214 shares (Direct)
Footnotes (4)
  1. F1. On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
  2. F2. This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  3. F3. Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
  4. F4. This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Total shares sold 26,756 shares of Common Stock Open-market sales on August 20, 2026 reported by Kevin R. Sayer
Sale price block 1 $89.706 per share 19,308 shares sold; trades executed in $89.275–$90.25 range, weighted average price reported
Sale price block 2 $90.7811 per share 7,351 shares sold; trades executed in $90.32–$91.19 range, weighted average price reported
Sale price block 3 $91.41 per share 97 shares sold in a separate non-derivative transaction on August 20, 2026
Unvested restricted stock units 106,972 RSUs Equity awards held by Kevin R. Sayer, vesting through March 8, 2027 and March 8, 2028
RSUs granted March 8, 2026 32,749 RSUs Unvested; scheduled to vest through March 8, 2027
RSUs granted March 8, 2025 56,993 RSUs Unvested; scheduled to vest through March 8, 2028
RSUs granted March 8, 2024 17,230 RSUs Unvested; scheduled to vest through March 8, 2027
Rule 10b5-1 Plan regulatory
"On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock units financial
"Included in this number are 106,972 unvested restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sale price financial
"The price above reflects the weighted average sale price."
open market or private transaction financial
"Sale in open market or private transaction"

FAQ

What insider transaction did DXCM Executive Chair Kevin R. Sayer report?
Kevin R. Sayer reported selling 26,756 shares of Dexcom common stock on August 20, 2026 in three open-market transactions. All transactions involved Common Stock and were coded as S, indicating sales in open market or private transactions.

At what prices were the DXCM shares sold by Kevin R. Sayer?
The reported sales occurred at weighted average prices of about $89.706 for 19,308 shares, $90.7811 for 7,351 shares, and $91.41 for 97 shares. Footnotes state these were executed in multiple trades within ranges of $89.275–$90.25 and $90.32–$91.19 where applicable.

Were Kevin R. Sayer’s DXCM stock sales under a Rule 10b5-1 plan?
Yes. A footnote states that on February 18, 2026, Kevin R. Sayer adopted a Rule 10b5-1 Plan allowing the orderly disposition of shares he owns, and that the shares sold on August 20, 2026 were sold pursuant to this 10b5-1 Plan.

How many unvested restricted stock units does Kevin R. Sayer have at Dexcom (DXCM)?
A footnote states that Sayer has 106,972 unvested restricted stock units, consisting of 32,749 RSUs granted March 8, 2026 vesting through March 8, 2027, 56,993 RSUs granted March 8, 2025 vesting through March 8, 2028, and 17,230 RSUs granted March 8, 2024 vesting through March 8, 2027.

Does the Form 4 show Kevin R. Sayer’s total DXCM share holdings after these sales?
The non-derivative transaction rows do not report a numeric value for total shares following transaction. A footnote notes that the reported number includes 106,972 unvested restricted stock units, but the exact total share count after the sales is not provided in these data.

Did the DXCM Form 4 report any derivative transactions for Kevin R. Sayer?
No. The filing’s structured data show only non-derivative transactions in common stock and a derivativeTransactionCount of 0 in the transaction summary, indicating no option exercises, conversions, or other derivative transactions were reported in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SAYER KEVIN R
(Last)(First)(Middle)
6340 SEQUENCE DRIVE
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Executive Chair
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/20/2026S19,308(1)D$89.706(2)309,662(3)D
Common Stock08/20/2026S7,351(1)D$90.7811(4)302,311(3)D
Common Stock08/20/2026S97(1)D$91.41302,214(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
2. This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
3. Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
4. This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Remarks:
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Kevin R. Sayer08/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR